Natural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Research and Development Efeom Nutrition S/A, São Paulo, SP, Brazil.
Front Endocrinol (Lausanne). 2023 Jan 27;13:1089938. doi: 10.3389/fendo.2022.1089938. eCollection 2022.
It is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters.
Sedentary volunteers (women and men) with body mass index (BMI) ≤34.9 kg/m were divided into two groups: Novel Nutraceutical Supplement_(S) (n = 30) and Novel Nutraceutical Supplement (n = 29), differing in the absence (S) or presence of silymarin, respectively. Volunteers were instructed to take two capsules in the morning and two capsules in the evening. No nutritional intervention was performed during the study period. The data (anthropometrics and anamneses) and harvest blood (biochemistry and hormonal exams) were collected at three different time points: baseline time [day 0 (T0)], day 90 (T90), and day 180 (T180) post-supplementation.
In the anthropometric analysis, the waist circumference in middle abdomen (WC-mid) and waist circumference in iliac crest (WC-IC) were reduced. Also, the waist-to-height ratio (WHt R) and waist-to-hip ratio (WHR) seem to slightly decrease alongside the supplementation period with both nutraceutical supplements tested as well as transaminase enzyme ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)], a known as a biomarker of NAFLD, and endocrine hormones cortisol and thyroid-stimulating hormone (TSH) at 90 and 180 days post-supplementation.
In a condition associated with sedentary and no nutritional intervention, the new nutraceutical supplement composition demonstrated the ability to be a strong and newfangled tool to improve important biomarkers associated with obesity and its comorbidities.
众所周知，肥胖是一种多因素病因，涉及遗传和环境因素。世界卫生组织估计，全世界有 19 亿超重成年人和超过 6.5 亿人肥胖。这些令人震惊的数据突显了肥胖的高发病率和不断上升，以及代表了非酒精性脂肪性肝病（NAFLD）等其他慢性疾病发展和恶化的风险因素，NAFLD通常被认为是 2 型糖尿病的肝脏结局。与传统药物相比，使用食品补充剂、营养保健品和天然综合疗法等非药物疗法作为肥胖相关疾病的替代工具已经增加。然而，这是一个研究领域仍在探索中，缺乏治疗效果的科学证据。考虑到这一点，目的是评估新的营养保健品配方是否可以改善和提供必需的矿物质营养，提供肥胖相关代谢和内分泌参数的改善。
将身体质量指数（BMI）≤34.9kg/m 的久坐志愿者（女性和男性）分为两组：新型营养保健品_（S）（n=30）和新型营养保健品（n=29），分别在补充剂中含有或不含水飞蓟素。志愿者被指示每天早晚各服用两粒胶囊。在研究期间不进行任何营养干预。数据（人体测量和病史）和收获血液（生化和激素检查）在三个不同时间点收集：基线时间[第 0 天（T0）]、第 90 天（T90）和第 180 天（T180）补充后。
在人体测量分析中，中腹部腰围（WC-mid）和髂嵴腰围（WC-IC）减少。此外，随着补充期的进行，腰围与身高的比值（WHt R）和腰围与臀围的比值（WHR）似乎也略有下降，以及两种营养保健品测试的转氨酶酶比值[天冬氨酸氨基转移酶（AST）/丙氨酸氨基转移酶（ALT）比值（AAR）]、非酒精性脂肪性肝病的生物标志物和内分泌激素皮质醇和促甲状腺激素（TSH）在补充后 90 和 180 天。
在与久坐和无营养干预相关的情况下，新型营养保健品配方显示出成为改善与肥胖及其合并症相关的重要生物标志物的强大和新颖工具的能力。
